Plasma concentration monitoring of busulfan: Does it improve clinical outcome?

Clinical Pharmacokinetics

Volumn 39, Issue 2, 2000, Pages 155-165

  McCune, J S ^a,b   Gibbs, J P ^b   Slattery, J T ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE;

AREA UNDER THE CURVE; CHRONIC MYELOID LEUKEMIA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MONITORING; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LIVER VEIN OBSTRUCTION; PRIORITY JOURNAL; RELAPSE; REVIEW; TREATMENT OUTCOME;

EID: 0033823462     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200039020-00005     Document Type: Review

References (54)

1. Pharmacokinetic and metabolic studies of high-dose busulphan in adults
2. Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia
3. Association of busulfan area under the curve with veno-occlusive disease following BMT
4. Pharmacokinetics of high-dose busulfan in children
5. Disposition of high-dose busulfan in pediatric patients undergoing bone marrow transplantation
6. Busulfan bioavailability
7. The impact of obesity and disease on busulfan oral clearance in adults
8. Busulfan disposition in children
9. 2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation?
10. Binding of busulfan to plasma proteins and blood cells
11. Cerebrospinal fluid and plasma concentrations of busulfan during high-dose therapy
12. Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology
13. Intravenous vs. oral busulfan as part of a BU/CY preparative regimen for allogeneic hematopeietic stem cell transplantation: Decreased incidence of hepatic veno-occlusive disease
14. Busulfan kinetics
15. Busulfan-glutathione conjugation catalyzed by human liver cytosolic glutathione S-transferases
16. Busulfan conjugation by glutathione S-transferases alpha, mu, and pi
17. Up-regulation of glutathione S-transferase activity in enterocytes of young children
18. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics [published erratum appears in Bone Marrow Transplant 1996 Oct; 18 (4): 829]
19. Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan
20. Liver volume as a determinant of drug clearance in children and adolescents
21. Busulfan pharmacokinetics in bone marrow transplant patients: Is drug monitoring warranted?
22. Busulfan disposition below the age of three: Alteration in children with lysosomal storage disease
23. Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders
24. Pharmacokinetic study of busulfan in an AML patient treated with regular hemodialysis [letter]
25. Busulfan clearance in renal failure and hemodialysis
26. Pharmacokinetics of busulfan: Correlation with veno-occlusive disease in patients undergoing bone marrow transplantation
27. Busulfan disposition: The role of therapeutic monitoring in bone marrow transplantation induction regimens
28. Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassaemia
29. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients
30. First dose area under the curve (AUC) of oral busulfan predicts risk of developing veno-occlusive diseases (VOD) in adult allogeneic bone marrow transplant (BMT) patients [abstract]
31. Pharmacokinetics of oral busulphan in children with beta thalassaemia major undergoing allogeneic bone marrow transplantation
32. An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease
33. Cellular target of cyclophosphamide toxicity in the murine liver: Role of glutathione and site of metabolic activation
34. Venoocclusive disease of the liver and cyclophosphamide pharmacokinetics: A prospective study in marrow transplant patients
35. Marrow transplantation for chronic myeloid leukemia: The influence of plasma busulfan levels on the outcome of transplantation
36. Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: Phase I dose escalation of busulfan based on targeted plasma levels
37. Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation
38. Busulfan pharmacokinetics do not predict relapse in acute myelogenous leukemia
39. Engraftment rates related to busulphan and cyclophosphamide dosages for displacement bone marrow transplants in fifty children
40. Optimization of busulfan dosage in children undergoing bone marrow transplantation: A pharmacokinetic study of dose escalation
41. Target dose adjustment of busulfan using pharmacokinetic parameters in pediatric patients undergoing bone marrow transplantation for malignancy or genetic disease
42. Plasma busulfan levels influence rejection in bone marrow transplantation for homozygous beta thalassaemia
43. Pharmacokinetic optimisation of cancer chemotherapy: Effect on outcomes
44. Therapeutic drug monitoring opportunities in cancer therapy
45. Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation
46. Target dose adjustment of busulfan using pharmacokinetic parameters in pediatric patients undergoing bone marrow transplantation for malignancy or inborn errors
47. Quantification of busulfan in plasma by gas chromatography-mass spectrometry following derivatization with tetrafluorothiophenol
48. Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: Phase I dose escalation of busulfan based on targeted plasma levels
49. Target dose adjustment of busulfan using pharmacokinetic parameters in pediatric patients undergoing bone marrow transplantation
50. An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children